Targeting BRAF mutants in clear-cell sarcomas of soft tissue: beyond sarcoma or melanoma classification

Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research

Related Links:

Conditions:   Non Small Cell Lung Cancer;   Advanced Solid Tumor;   Metastatic Melanoma;   Metastatic Head and Neck Carcinoma;   Metastatic Renal Cell Carcinoma;   Metastatic Colorectal Cancer;   Sarcomas;   Metastatic Prostate Cancer Interventions:   Drug: ONC-392;   Drug: Pembrolizumab Sponsor:   OncoImmune, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: In selected patients, local treatments contribute to controlling oligoprogression for a long time, allowing the continuation of systemic treatment and prolongation of overall survival (OS). Increasing biological and clinical knowledge is improving the accuracy in identifying patients to apply for local ablative therapies.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Communication Source Type: research
CONCLUSIONS: Our findings highlight the importance of carefully inspecting CD45-negative events to identify non-HNs by routine FC analysis. This can help expedite further downstream immunophenotypic analysis of specimens and triage samples for appropriate genetic and molecular studies. PMID: 31587038 [PubMed - as supplied by publisher]
Source: American Journal of Clinical Pathology - Category: Pathology Authors: Tags: Am J Clin Pathol Source Type: research
AbstractBackgroundNon-hematopoietic malignancies first presented as an axillary mass constitute a unique clinical presentation. We investigated the incidence of various types of malignancies and aimed to define clinicopathologic variables that may assist in the diagnosis, with focus on occult breast carcinoma (OBC).DesignWe reviewed the pathology reports of cases with non-hematopoietic malignancies of the axillary region in our institution between 2000 and 2016. We included patients who presented first with axillary mass and with the absence of a known primary. We recorded patients ’ age and gender, tumor characteris...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
This study investigated the prevalence and the distribution of FGFR aberrations in Chinese cancer patients.MethodsWe screened genomic profiling results of plasma or tissue samples from 10,582 patients spanning 16 cancer types: lung, breast, gastric, hepatobiliary, pancreatic, soft tissue sarcoma, esophageal, ovarian, colorectal, head and neck, renal, endometrial, osteogenic sarcoma, cervical, melanoma and lymphoma.ResultsOf the 10,582 patients screened, we observed 745 patients with FGFR aberrations, revealing an overall prevalence of 7.03%. Approximately, 3.78% harbored FGFR amplification, 2.73% had other mutations and 0....
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
AbstractBackgroundNY-ESO-1 and LAGE-1a are antigens expressed in several tumours, including non-small cell lung cancer (NSCLC). Previous clinical trials using autologous T cells directed against NY-ESO-1/LAGE-1a have shown objective responses between 40% and 60% in synovial sarcoma, metastatic melanoma and multiple myeloma. Pembrolizumab (PEM) is a monoclonal antibody that blocks PD-1/PD-L1 interaction and increases anti-tumour activity in anti-tumour T cells. Here, PEM will be used in combination with NY-ESO-1/LAGE-1a T-cell receptor engineered patient T cells (GSK3377794) to potentially improve clinical benefit in this p...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsACT with TBI-1301 cells is safe and clinically active. Results provided here confirm long-term persistence of gene-engineered T cells with higher frequencies of CD45RA+ CCR7+ CD8+ T cells in responding patients. Detailed biomarker analysis of persisting TBI-1301 cells will be presented.Clinical trial identificationNCT02869217.Legal entity responsible for the studyThe authors.FundingPrincess Margaret Cancer Foundation, Takara Bio, Inc.DisclosureM.O. Butler: Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Spea...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe affinity-enhanced NY-ESO-1/TCR-T cell transfer exhibited early-onset CRS in association with in vivo cell proliferation and sequential tumor responses in the patients with high-NY-ESO-1-expressing synovial sarcoma.Clinical trial identificationNCT02366546.Legal entity responsible for the studyThe authors.FundingJapan Agency for Medical Research and Development.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Both canine cutaneous histiocytoma and cutaneous lymphoma should be considered at the beginning of differential diagnosis for CCRCTs. While most poorly differentiated CCRCTs can be diagnosed immunohistochemically using 1-4 basic antibodies, some require a broad antibody panel, including mesenchymal, epithelial, myogenic, and melanocytic markers. The expression of Iba1 is specific for canine cutaneous histiocytic tumours, and more sensitive than CD18. The utility of CD20 in the diagnosis of CCRCTs is limited. PMID: 31553052 [PubMed - as supplied by publisher]
Source: Folia Histochemica et Cytobiologica - Category: Cytology Tags: Folia Histochem Cytobiol Source Type: research
ConclusionsAnaplastic thyroid carcinomas show significantly higher expression of CD1d, a receptor for NKT cells, which are subject of several anticancer therapy studies. These results may offer a novel approach to explore immunotherapeutic treatment options.
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
More News: Drugs & Pharmacology | Investigational New Drugs | Melanoma | Sarcomas | Skin Cancer